PepTcell Limited – Product Pipeline Review – Q4 2010

Date: December 1, 2010
Pages: 33
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: P6E5C08FA17EN
Leaflet:

Download PDF Leaflet

PepTcell Limited – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “PepTcell Limited – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • PepTcell Limited – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of PepTcell Limited human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of PepTcell Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the PepTcell Limited’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate PepTcell Limited’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of PepTcell Limited in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the PepTcell Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with PepTcell Limited.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of PepTcell Limited and identify potential opportunities in those areas.
PepTcell Limited Snapshot
PepTcell Limited Overview
Key Information
Key Facts
PepTcell Limited – Research and Development Overview
Key Therapeutic Areas
PepTcell Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
PepTcell Limited – Pipeline Products Glance
PepTcell Limited Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
PepTcell Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
PepTcell Limited – Drug Profiles
HIV Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
Flu-v
  Product Description
  Mechanism of Action
  R&D Progress
Vaccine for Hepatitis B Infection
  Product Description
  Mechanism of Action
  R&D Progress
Breast Cancer Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
Mosquito-Borne Disease Prophylactic Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
T Cell Therapeutic Vaccine for Hepatitis C Infection
  Product Description
  Mechanism of Action
  R&D Progress
T Cell Therapeutic Vaccine For Viral Infections
  Product Description
  Mechanism of Action
  R&D Progress
PepTcell Limited – Pipeline Analysis
PepTcell Limited – Pipeline Products by Therapeutic Class
PepTcell Limited Pipeline Products By Target
PepTcell Limited – Pipeline Products by Route of Administration
PepTcell Limited – Pipeline Products by Molecule Type
PepTcell Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 24, 2009: PepTcell To Start Phase Ib Clinical Trials For Novel HIV Vaccine
Jun 18, 2007: PepTcell Announes The Preclinical Data At Options For The Control Of Influenza VI Conference
Apr 07, 2007: PepTcell Starts Safety Studies For Novel T-cell HIV Vaccine
Financial Deals Landscape
PepTcell Limited, Deals Summary, 2004 to 2010
PepTcell Limited Detailed Deal Summary
Licensing Agreements
Biocopea Enters Into Licensing Agreement With Sosei Group
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

PepTcell Limited – Pipeline by Therapy Area and Indication, 2010
PepTcell Limited – Pipeline by Stage of Development, 2010
PepTcell Limited – Monotherapy Products in Pipeline, 2010
PepTcell Limited - Phase I, 2010
PepTcell Limited - Pipeline By Therapeutic Class, 2010
PepTcell Limited - Pipeline By Target, 2010
PepTcell Limited – Pipeline By Route of Administration, 2010
PepTcell Limited – Pipeline By Molecule Type, 2010
PepTcell Limited, Other Locations
PepTcell Limited, Subsidiaries
PepTcell Limited, Deals Summary, 2004 to 2010 30

LIST OF FIGURES

PepTcell Limited – Pipeline by Therapy Area and Indication, 2010
PepTcell Limited – Pipeline by Stage of Development, 2010
PepTcell Limited – Monotherapy Products in Pipeline, 2010
PepTcell Limited – Pipeline By Therapeutic Class, 2010
PepTcell Limited - Pipeline By Target, 2010
PepTcell Limited – Pipeline By Molecule Type, 2010 25

Ask Your Question

PepTcell Limited – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: